Frequency of Clopidogrel Resistance in Patients of Ischemic Heart Disease
|
|
- Loreen Hutchinson
- 5 years ago
- Views:
Transcription
1 ISCHEMIC HEART DISEASE ORIGINAL RESEARCH Frequency of Clopidogrel Resistance in Patients of Ischemic Heart Disease Syed Khizar Abbas Rizvi 1, Shahida Mohsin 1, Tahir Saeed 2, Saeed Ahmad 3, Shabbir Hussain 1 Muhammad Ikram Ullah 2 Received: 14/3/13, Reviewed 10/4/13, Accepted: 16/4/13 Key words: Clopidogrel, Ischemic Heart Disease, platelet Aggregation, Platelet Aggregation Inhibitors DOI: /ejcm ABSTRACT: Clopidogrel and Aspirin are widely used antiplatelet agents in the prevention and treatment of ischemic heart disease (IHD). Many patients have been noticed with recurrence of major ischemic events, due to resistance of these drugs. Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel. The objective of this study was to determine frequency of clopidogrel resistance in patients of ischemic heart disease. Seventy one patients of IHD were selected from out-patient department of Punjab Institute of Cardiology Platelet aggregation studies were performed on Diamed Impact R. Clopidogrel response assay was performed with DiaAdin(ADP 110µmol/L). Chi-square test was applied to measure statistical significance. Resistance to Clopidogrel was observed in 17% (12 out of 71). Clopidogrel resistance was significantly associated with female gender (p=0.046). In our study no statistically significant association was observed between clopidogrel resistance and risk factors like diabetes mellitus, family history ischemic heart disease, hypertension and smoking. We concluded that resistance to Clopidogrel therapy is seen in significant number of patients and female patients are at high risk of developing the resistance to clopidogrel therapy. These patients can be identified by performing platelet aggregation studies on Impact R. 1. Department of Haematology, 2. Department of Biochemistry, 3. Department of Pathology, Sharif Medical and Dental College 4. Hussani Blood Transfusion Centre Karachi CORRESPONDENCE Syed Khizar Abbas Rizvi, MBBS, M.Phil Department of Haematology, Lahore INTRODUCTION Ischemic heart disease is a major public health problem and a leading cause of death in the world. Its risk increases with age, smoking, hypercholesterolemia, diabetes and hypertension [1]. Currently, cardiovascular diseases accounts for 16.7 million deaths worldwide each year and strategies for improving prevention and management of thrombotic conditions are required [2]. The most commonly used antiplatelet drugs are Acetylsalicylic acid (Aspirin) and thienopyridines (clopidogrel). Clopidogrel is a prodrug, which needs to be metabolized in the liver to active metabolites. Clopidogrel inhibits the ADP receptor P2Y12, and thereby inhibiting the ADP mediated platelet activation. In vivo transformation of clopidogrel to active metabolites is an important and critical step for the drug effect. This metabolisation is dependent on the hepatic cytochrome P450 isoenzymes like CYP2C19, CYP1A2, CYP2B6, CY- P2C9 and CYP3A4 [3]. One of the key enzymes in clopidogrel metabolism is CYP2C19, which is involved in both stages of clopidogrel biotransformation [4,5]. A number of studies have shown that aspirin or clopidogrel resistance is associated with increased risk of recurrent cardiovascular events [6,7].The term resistance is used to indicate failure of an agent to prevent the clinical condition for which it is used or failure of the agent to achieve the biochemical (pharmacokinetic and/or pharmacodynamic) effect [8]. Different platelet function tests have been used to measure the degree of platelet inhibition in patients treated with clopidogrel. Light transmission aggregometry with ADP as an agonist, is the most used method, but the test is time consuming and not practical for routine use. New point of care devices like PFA100, VerifyNow and The cone and plate(let) analyser are being utilised for the determination of antiplatelet therapy effectiveness. The PFA-100 measures the fall in flow rate as platelets within citrated whole blood are aspirated through a capillary and begin to seal a 150μm aperture within a collagen coated membrane. The disadvantages of PFA 100 are: This is inflexible, VWF dependent, Haematocrit dependent and insensitive to clopidogrel [9]. Contact No khizarabbas14@gmail.com LIMITATIONS OF STUDY Our study was a descriptive study with its limitations. The exact prevalence of clopidogrel resistance may be different from the one which is observed in the present study. ACKNOWLEDGEMENTS We acknowledge University of Health Sciences, Lahore, Pakistan for technically supporting this research project. We also extend our gratitude to the participants of the study. CONFLICTS OF INTEREST We are grateful to, Lahore, Pakistan for providing financial support to pursue this research project. There are no conflicts of interest. ISSN EUROPEAN JOURNAL OF CARDIOVASCULAR MEDICINE VOL II ISSUE III
2 FREQUENCY OF CLOPIDOGREL RESISTANCE IN PATIENTS OF ISCHEMIC HEART DISEASE VerifyNow is fully automated platelet aggregometer which can be used to monitor the therapy of aspirin, clopidogrel and GpIIbIIIa inhibitors but this assay is expensive and Cartridges can only be used for single purpose [9]. The cone and plate(let) analyser, originally developed by Varon and Savion, monitors platelet adhesion and aggregation to a plate coated with collagen or extracellular matrix (ECM) under high shear conditions of 1800 s 1 [10]. In the Commercial version of the device, the Impact (DiaMed), a plastic plate is utilized instead of a collagen or an ECM-coated surface. Figure 1: Illustration of test report of clopidogrel resistance in a patient. (Processed on Diamed Impact-R, Software Version: 1.28). In this study we used Diamed Impact R to determine the frequency of resistance of clopidogrel in patients of IHD. Diamed Impact R is the instrument which provides the physiological condition for platelet adhesion and aggregation. Platelet adhesion and aggregation on the polystyrene surface is evaluated using an image analysis system. The results are expressed as the percentage of surface covered (%SC) by platelets and the average particle size (AS; micron m2). Normal value of % SC is >7.5 and AS is >25 micron m2 for physiological platelet function. PATIENTS AND METHODS Study Population It was a descriptive cross sectional study conducted at the department of Haematology, Lahore in collaboration with Punjab Institute of Cardiology, Lahore Pakistan. The study was approved by ethical committee of University of health sciences Patients were enrolled after informed written consent from April March Diagnosed patients of IHD who were more than 21 years of age and on Clopidogrel 75 mg for at least more than 07 days were included in study and patients who have Family or personal history of bleeding disorders, Platelet count <150 or > /L, Hemoglobin <8 g/dl, Major surgical procedure within one week before enrollment and Administration of un-fractionated or low molecular weight heparin within 24 hours before enrollment were excluded from study. Laboratory Techniques 5ml of venous blood was collected using aseptic methods. Citrated whole blood (3ml) was used for platelet studies (platelet adhesion and aggregation) using Impact R (Diamed, Israel). DiaAdin (ADP110µmol/L) was used as platelet agonist. 2ml blood (in EDTA) was used to determine Haemoglobin, Haematocrit and platelet count using Sysmex XI-1800 (manufact). Resistance to Clopidogrel therapy was assessed by Impact R on the basis of software generated results: Surface covered (SC) > 2.8% was considered as response to clopidogrel and SC < 2.8 % was considered as no response (or Resistance) to Clopidogrel. Resistance to clopidogrel therapy in a patient is illustrated in Figure 1. Data Collection Data about patient s demographic features (age, sex, and address), clinical diagnosis, duration of illness, drug intake history, history of recurrent ischemic events and relevant clinical history was obtained on a specially designed proforma. The data about platelet aggregation studies was entered after performing the laboratory tests in the specified columns. *SC: Surface Covered; *AS: Average Size; *Ob: Object Number Statistics All data was entered and analysed with the help of SPSS version The quantitative variables were expressed as mean+sd. Chisquare test was applied to measure the statistical significance of frequency of drug resistance between groups e.g. Diabetics vs. Non-diabetics, Males vs. Females. A p value of less than 0.05 was considered for statistical significance. RESULTS Out of 71 patients 37 patients had IHD without PCI (Percutaneous Coronay Intervention) or CABG (Coronary Arterial Bypass Grafting). Nineteen patients had IHD with Angioplasty and 15 patients were treated with CABG. Mean Age in the study population in years was (95% CI ) Median duration of illness in the study population was (Tukeys s Hinges: 9-48) months. Demographic Characteristics of study population are shown in Table 1. Hemoglobin, Hematocrit and platelet count were measured for each subject before performing the platelet aggregation studies to fulfill exclusion criteria for Hb, HCT% and platelet count (Table 2). EUROPEAN JOURNAL OF CARDIOVASCULAR MEDICINE VOL II ISSUE III 177
3 HEALTHCARE BULLETIN ISCHEMIC HEART DISEASE Table 1: Demographic Data of the Subjects included in the Study Variables Frequency Percentage% Resistant P-Value Male >0.05 Female DM >0.05 HTN >0.05 Family H/o IHD >0.05 Rec. ischemia >0.05 Smokers >0.05 *DM: Diabetes Mellitus *HTN: Hypertension *IHD: Ischemic Heart Disease *Rec: Recurrent Table 2: Demographic Data of the Subjects included in the Study Figure 2: Frequency of Clopidpgrel Resistance Laboratory Parameters Mean+SD Hb of the patients (g/dl) 13.38±1.42 ( ) Hct. of the patients (%) 40.05±3.20 ( ) Platelets count of the patient (109/L) 252.0±70.9 ( ) *Hb: Haemoglobin *Hct: Hematocrit *SD:Standard Deviation Figure 3: Comparison of % SC (Surface Covered) of Clopidogrel Response Assay between male and female patients Clopidogrel Response Assay Out of 71 patients12 (17%) were found resistant to clopidogrel. The frequency of resistance to clopidogrel is shown in Figure 2. Samples of resistant patients were retested, without DiaAdin to assess any baseline platelet functional aggregation defect. No case was found to have any platelet functional defect. There was significant association (P value of 0.046) between resistance to Clopidogrel and patients with female gender. It was also observed that variance in % SC (surface covered) was higher in female patients as compare to male patients. Variance of %SC of male and female patients is shown in Figure 3. Significant association of Clopidogrel resistance and other risk factors like hypertension, diabetes mellitus, smoking and family history of ischemic heart disease was not observed (p value of >0.05) (Table 1). 178 EUROPEAN JOURNAL OF CARDIOVASCULAR MEDICINE VOL II ISSUE III
4 FREQUENCY OF CLOPIDOGREL RESISTANCE IN PATIENTS OF ISCHEMIC HEART DISEASE DISCUSSION Antiplatelet therapy is effective in primary and secondary prevention of atherothrombotic events in patients of ischemic heart disease [11].The concept of clopidogrel resistance has emerged in the medical literature to reflect the failure to inhibit platelet function in vitro, although its existence and definition remain to be established. It has been proposed that the term resistance encompasses patients for whom clopidogrel does not achieve its pharmacological effect, and failure of therapy reflects patients who have recurrent events on therapy [12]. Despite intensified antiplatelet treatment, up to 4.7% of the patients undergoing coronary stenting develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to clopidogrel resistance [13]. The prevalence of clopidogrel non-response in patients is estimated 4% to 30% [14].The reported rates vary between studies because of the technique used to measure the extent of platelet aggregation and the presence of factors contributing to platelet reactivity [15]. In our study non responders to clopidogrel were 12 (17%) and all patients were on standard dose of 75mg OD. Clopidogrel assay was measured with DiaAdin (ADP110 µmol/l) on Diamed Impact R. In another study 16% of Coronary arterial disease (CAD) patients were classified as non-responders and the electrical impedance aggregometry was performed in diluted whole blood in the presence of 5 and 20 μmol/l ADP [16]. In a study by Mobley et al. (2004) the prevalence of clopidogrel resistance was estimated 30%. These patients were on 75 mg daily maintenance dose and the method used was Optical aggregometry 1 µmol/l ADP. A study conducted in India, 2.54% patients were found to be clopidogrel resistant, 12.7% were clopidogrel semiresponders and 84.7% were clopidogrelresponders and the optical aggregometry was used to define clopidogrel resistance, semiresponders and responders [17]. Estimated frequency of clopidogrel resistance in different studies is summarised in Table 3. In our study no significant association was observed between clopidogrel resistance and risk factors like diabetes mellitus, family H/O ischemic heart disease, hypertension and smoking. However resistance to clopidogrel therapy was noted more in female patients with a statistically significant P value (P = 0.046). In a study by Boris et al. (2006) it was reported that female are predisposed to clopidogrel resistance (P = ) This marked sex-related difference in clopidogrel responsiveness needs to be confirmed in a larger number of patients matched for other potential confounders. Similarly various risk factors like age, smoking, diabetes, hypertension, obesity, cholesterol, did not show any statistically significant difference among the groups in a study by Kumar et al. (2007). Class IIB recommendations from the American College of Cardiology (ACC)/American Heart Association (AHA) have stated that platelet aggregation studies are warranted in patients undergoing PCI who are at risk of sub-acute stent thrombosis, with the option of increasing their maintenance dose of clopidogrel from 75 to 150mg/day in order to suppress platelet reactivity below 50% [18]. Recent studies have evaluated the effect of modifying therapy on clinical outcome for patients deemed non-responsive as measured by platelet function tests. Clopidogrel response can also vary because of inter-individual differences in drug absorption, resulting in lower levels of the active metabolite. Medications such as statins and certain proton pump inhibitors have been proposed to affect the metabolisation of clopidogrel by the CYP isozyme 3A4, although data is controversial [19,20]. Individuals with low baseline metabolic activity of the CYP3A4 enzyme have also been shown to have poor clopidogrel responsiveness and this aspect should be evaluated on large randomised trials [21]. It is concluded that resistance to clopidogrel therapy is seen in significant proportion of patients. These patients can be identified by performing platelet aggregation studies on Diamed Impact R and female patients are at high risk for developing the resistance to clopidogrel therapy. Table 3: Clopidogrel resistance in different studies Authors Year Estimated Resistance Method Müller et al % Optical aggregometry Jaremo et al % Optical Aggregometry Mobley et al % Optical Aggregometry Boris et al % Optical Aggregometry Kumar et al % Optical aggregometry Boris et al % Impedence aggregometry Our study % Impact R EUROPEAN JOURNAL OF CARDIOVASCULAR MEDICINE VOL II ISSUE III
5 HEALTHCARE BULLETIN ISCHEMIC HEART DISEASE REFERENCES Ruggeri, ZM. Platelets in atherothrombosis. Nat Med 2004; 8: Frans,Van de. and Werf, J. Dual antiplatelet therapy in high-risk patients. Eur Heart J.Suppl2007;(suppl D): D3-D9. Pettersen,AA., Arnesen,H., Opstad TB, Seljeflot,I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thrombosis Journal 2011;9:4 Hulot, J.S., Bura, A., Villard, E. Cytochrome P450 2C19 loss of function polymorphism is a major determinant ofclopidogrel responsiveness in healthy subjects. Blood 2006; 108: Kazui,M.,Nishiya,Y., Ishizuka,T. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidativesteps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug MetabDispos2010; 38: Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336: Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman, MV. Clopidogrelnonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154: Florian, K., Hae-Young, S., Volker, K. (2008) Antiplatelet drugs in cardiological practice: Established strategies and new developments.isvh 2008;4(3): Harrison, P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10 Spectre, G., Brill, A., Gural, A., Shenkman, B., Touretsky, N., Mosseri, E., et al. A new point-of care method for monitoring antiplatelet therapy: Application of the cone and plate(let) analyzer. Platelets 2005 ;16: Antiplatelet Trialist Collaboration Collaborative overview of randomized trial of antiplatelet therapy. Prevention of death, myocardial infarction and stroke in prolonged antiplatelet therapy in various categories of patients.bmj 1994; 308: Gum,PA., Kottke-Marchant, K., Poggio, ED., Gurm, H.,Welsh, PA., Brooks, L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am.J. Cardiol2001;88: Wiviott, SD. And Antman, EM.Clopidogrel resistance: A new chapter in a fast-moving story. Circulation 2004;109: Muller, I., Besta, F., Schulz, C. (2003).Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. ThrombHaemost2003; 89:783 7 Nguyen,T.A., Diodati,J.G, Chantal, Pharand. Resistance to Clopidogrel: A Review of the Evidence, Cardiol 2005; 45: Jaremo, P., Lindahl, TL.,Fransson, SG., Richter, A.(2002). Individual variationsof platelet inhibition after loading doses of clopidogrel. J Intern Med.2002; 252:233 8 Boris,T.Ivandica., Philipp Schlick., Peter Staritz., Kerstin Kurz., Hugo, AK., Evangelos, Giannitsis. (2006). Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.clinchem.2006;52: Kumar, S., Saran, RK., Puri, A., Gupta, N., Sethi, R., Surin, WR., et al. Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome. Indian Heart J.2007;59(2): Smith, SC., Feldman, TE.,Hirshfeld, JW. (2006). ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: Ajzenberg, N., Aubry, P., Huisse, MG.,Cachier, A., El Amara, W., Feldman, LJ., et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol.2005; 45: Jean-Philippe,C., Wouter van Werkum. (2010). Individualised antiplatelet therapy: Is there a role for platelet function testing in routine clinical practice? European Cardiology.2010;6(1): EUROPEAN JOURNAL OF CARDIOVASCULAR MEDICINE VOL II ISSUE III
JOINT MEETING OF CORONARY REVASCULARIZATION 2014 TIONG LEE LEN SENIOR RESEARCH PHARMACIST CLINICAL RESEARCH CENTER, SARAWAK GENERAL HOSPITAL
The Effect of Non Steady State and Steady State Clopidogrel Carboxylic Acid Plasma Concentration on Clopidogrel Responsiveness in Patients Planned For Percutaneous Coronary Intervention JOINT MEETING OF
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationAntiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO
Antiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO Assistant Professor of Neurology, Radiology, and Neurosurgery University of Texas Health Science Center - San Antonio
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationLow-dose aspirin increases aspirin resistance in patients with coronary artery disease
The American Journal of Medicine (2005) 118, 723-727 CLINICAL RESEARCH STUDY AJM Theme Issue: CARDIOLOGY Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Pui-Yin Lee,
More informationΔοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Εμμανουήλ Βαβουρανάκης Αναπλ. Καθηγητής Καρδιολογίας Ιπποκράτειο ΓΝΑ Haematology Research Laboratory!! Platelets Small anucleate discoid cells Involved
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationJournal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationMultiplate analyzer Cut-off-values ADPtest and ASPItest
Multiplate analyzer Cut-off-values ADPtest and ASPItest Cut-off values ADPtest The cut-off values were established in hirudin blood samples. Healthy individuals AUC (U) 1 Patient on ADP receptor antagonist
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPlatelet function testing in cardiovascular diseases
Hematology, 2005; 10 Supplement 1: 132 /137 PLATELET DISORDERS Platelet function testing in cardiovascular diseases ALAN D. MICHELSON From the Center for Platelet Function Studies, Departments of Pediatrics,
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationISAR-CHOICE 2. Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI
ISAR-CHOICE 2 Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Variability in Platelet Response to Clopidogrel Serebruany
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationAPPLICATION OF GENETIC TESTING FOR CYP 450 POLYMORPHISM TO PREDICT RESPONSE TO CLOPIDOGREL INPATIENT UNDERGOING PCI
INDIAN JOURNAL OF CARDIOVASCULAR DISEASES JOURNAL in women (IJCD) 2017 VOL 2 ISSUE 2 ORIGINAL ARTICLE 1 APPLICATION OF GENETIC TESTING FOR CYP 450 POLYMORPHISM TO PREDICT RESPONSE TO CLOPIDOGREL INPATIENT
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationPrevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary Artery Disease or Ischemic Cerebrovascular Disease
Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 39, no. 3, 2009 289 Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Patients with Coronary
More informationNew Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
October 23, 2006 Refer to: Joedy Isert Eli Lilly and Company 317-276-5592 (office) 317-997-8544 (cell) Jo-ann Straat Daiichi Sankyo (USA) 973-359-2602 (office) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationCase Report Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
Case Reports in Medicine Volume 2016, Article ID 2312078, 4 pages http://dx.doi.org/10.1155/2016/2312078 Case Report Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationEvaluation of Clopidogrel Resistance. in ischemic stroke patients.
ORIGINAL ARTICLE Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients Takuya Fukuoka, Daisuke Furuya, Hidetaka Takeda, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ichiro Deguchi, Hajime Maruyama,
More informationImpact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
More informationIMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationCase presentation 1: Mr F. is a
CLINICIAN UPDATE Platelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet
More informationand Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationDifferences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific?
Differences In Efficacy Of Antiplatelet Therapy-Is That Gender Specific? DR.O.SAI SATISH PROFESSOR DEPARTMENT OF CARDIOLOGY NIMS Death is inevitable but Premature death is not Sir Richard Doll Topic outline
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationClopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
More informationProton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel
Proton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel Dr.A.K.M. Aminul Hoque Assoc. Prof. of Medicine. Dhaka Medical College. Clopidogrel Metabolism Clopidogrel is an inactive
More informationJoint Meeting of Coronary Revascularization 8 th to 9 th December 2017
B Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017 A Novel Clinical Application Combining Genotyping and Platetlet Function Testing In Patients With Acs - A Case Series Shirley Tan
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationGENNARO SARDELLA MD, FACC,FESC
PhaRmacodynamic Effects of Switching therapy in PCI patients with high on Treatment platelet reactivity and genotype variation: high Clopidogrel dose versus Prasugrel (RESET GENE Study). (ClinicalTrials.gov
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationWhat hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationDaiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationAccess Site Complications. Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus
Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus Surgeons & Cardiologists Interventional Cardiology 2008 Eye of a Hawk,
More informationORIGINAL ARTICLE INTRODUCTION ORIGINAL ARTICLE
ORIGINAL ARTICLE DOI: 10.3904/kjim.2011.26.2.145 ORIGINAL ARTICLE Detection of Clopidogrel Hyporesponsiveness Using a Point-of-Care Assay and the Impact of Additional Cilostazol Administration after Coronary
More informationSupplementary Online Content
Supplementary Online Content Schulz Schüpke S, Helde S, Gewalt S; et al. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationApproval for publication Signed Date Number of amended pages returned
Approval for publication Signed Date Number of amended pages returned ORIGINAL RESEARCH ARTICLE Am J Cardiovasc Drugs 2009; 9 (6): 1-7 1175-3277/09/0006-0001/$49.95/0 ª 2009 Adis Data Information BV. All
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationA patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationMeasurement of Antiplatelet Therapeutic Efficacy
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology Research St Vincent Hospital Worcester MA Disclosure
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationSimple, Rapid Antiplatelet Therapy Response Assessment
Simple, Rapid Antiplatelet Therapy Response Assessment Acute Care Diagnostics Antiplatelet therapy. Is it working? At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationEFFIENT (prasugrel hydrochloride)
EFFIENT (prasugrel hydrochloride) NAME OF THE MEDICINE EFFIENT (prasugrel hydrochloride) The active ingredient is prasugrel hydrochloride. DESCRIPTION Prasugrel, an adenosine diphosphate (ADP) receptor
More information1. Introduction: Page 5. International Multispecialty Journal of Health (IMJH) [Vol-1, Issue-4, June- 2015]
Aspirin Resistance: A Review Dr. Kamlesh Sharma 1, Dr. Lokendra Sharma 2, Dr. Monica Jain 3, Dr. Gopal Jhalani 4, Dr. Shivankan Kakar 5, Dr. Harsh Yadav 6 1,3 Professor, Department of Medicine, SMS Medical
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationControversies in PCI A young cardiologist s perspective
Controversies in PCI A young cardiologist s perspective Antiplatelet Tx, PLT function monitoring should be mandatory CONTRA M. Valgimigli, MD, PhD Ferrara, Italy Euro-PCR Session @ ESC August 30th 2010,
More informationOlga Gorchakova a, Nicolas von Beckerath b, *, Meinrad Gawaz a, Adrienne Mocz b, Alexander Joost b, Albert Schömig a,b, Adnan Kastrati b.
European Heart Journal (24) 25, 1898 192 Clinical research Antiplatelet effects of a mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationHead-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Date: August 21, 2008 Refer to: Carole Copeland (OUS) Eli Lilly and Company 317-277-3661 (office) 317-610-6196 (cell) Tammy Hull (U.S.A.) Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell)
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More information